As per the research report titled ‘Global Synthetic Biology Market’ available with MarketStudyReport, global synthetic biology market is expected to amass a valuation of USD 39,579 million by the end of 2028, while progressing at a CAGR of 19.7% through the forecast timeframe.

Increasing R&D investments, rising number of innovation initiatives in the field of synthetic biology, and decreasing cost of DNA sequencing & synthesis are the major factors driving global synthetic biology market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4973414/   

For the uninitiated, synthetic biology refers to a process that combines molecular biology with engineering principles to design bio-factories. The process mainly aims to transform production and development of diagnostic procedures, vaccine implementation, and therapeutics in order to divulge important information pertaining to genomic sequences, algorithms, laboratory protocols, and enzyme properties among others.

Despite the positive outlook, ethical concerns and issues associated with safety & security are some of the major bottlenecks that industry players may have to overcome over the forecast duration.

Apart from this, the research literature educates the readers regarding the various segmentations of the market in terms of product spectrum (enabling products, core products, others), application scope (research, healthcare, food & agriculture, chemicals, others), and regional expanse (Europe, Asia Pacific, North America).

Each bifurcation is thoroughly analyzed on the basis of industry share, historic and current trends, along with growth potential over the analysis period for stakeholders to identify promising avenues for expansion, thereby improving their profitability graph.

Considering the competitive framework, Thermo Fisher Scientific Inc., DuPont de Nemours Inc., Koninklijke DSM N.V., Danaher Corporation, Agilent Technologies Inc., GenScript Biotech Corporation, Novozymes A/S, Amyris Inc., New England Biolabs, and Viridos (previously Synthetic Genomics Inc.) are the top contenders influencing global synthetic biology market trends.